AmpliPhi’s lead product candidates target areas of significant unmet clinical need, including multidrug-resistant S. aureus and P. aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List.
AmpliPhi’s product candidates have been delivered to humans intravenously, inhaled by nebulizer, topically, and intrasinally.
| Program | Indication | Phase |
|---|---|---|
| AB-SA01 (S. aureus) 1 | ||
| Intravenous | Endocarditis, Bacteremia, Prosthetic Joint Infection | Expanded Access |
| Intrasinal | Chronic Rhinosinusitis | Phase 1 Completed |
| Topical | Various | Phase 1 Completed |
| AB-PA01 (P. aeruginosa) 2 | ||
| Intravenous | Lung Infections, complicated Urinary Tract Infection, complicated Intra-Abdominal Infection | Expanded Access |
| Inhaled | Lung Infections, Cystic Fibrosis | Expanded Access |
| Other ESKAPE* Pathogens | Preclinical | |
| *ESKAPE pathogens are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species | ||
1Staphylococcus aureus (S. aureus)
Labeled as High priority by the World Health Organization (WHO) in Feb. 2017 on their Priority Pathogen List.
2Pseudomonas aeruginosa (P. aeruginosa)
Labeled as Critical priority by the WHO in Feb. 2017 on their Priority Pathogen List.